Quantum-Si Incorporated - QSI STOCK NEWS

Quantum-Si (NASDAQ: QSI) has announced key leadership appointments to enhance its commercial and operational capabilities as it scales its innovative Platinum™ protein sequencing platform. New roles include Katherine Atkinson as Senior VP of Demand Generation, Alex Hutcheson as Senior VP of Sales, Christine Nishiyama as VP of Supply Chain, and Dr. John Vieceli as VP of Algorithms. These executives bring extensive experience from notable firms, which is expected to drive growth in the company's emerging customer base. The advancements align with Quantum-Si's strategy to disseminate proteomic data through its unique single-molecule sequencing technology, aiming to impact various scientific disciplines in drug discovery and biotechnology.

Quantum-Si Incorporated (NASDAQ: QSI), known as The Protein Sequencing Company, will report its financial results for Q1 2023 on May 11, 2023, at 4:30 PM ET. The announcement includes a conference call for management to discuss the results and provide a business update. Interested parties can join the live webcast or register online for a dial-in number. Quantum-Si is pioneering in the proteomics sector, utilizing a unique semiconductor chip for next-generation single-molecule protein sequencing, impacting drug discovery and diagnostics.

Quantum-Si Incorporated (NASDAQ: QSI), known as The Protein Sequencing Company™, will present a new method for detecting arginine post-translational modifications (PTMs) using its innovative Platinum™ single-molecule protein sequencing platform at the AACR Annual Meeting 2023. Scheduled from April 14-19 in Orlando, Florida, Dr. Kenneth Skinner will showcase the findings on April 18 from 1:30-5:00 p.m. The results suggest that single-molecule sequencing could outperform traditional methods like mass spectrometry, which often struggle with low abundance and mass differences. This advancement could enhance biomarker development and drug discovery in cancer research. With its compact design and competitive price point of $70,000, Platinum aims to revolutionize proteomics research.

Quantum-Si Incorporated (NASDAQ: QSI), known as The Protein Sequencing Company, announced its participation in the B. Riley Securities' Life Sciences Tools Conference on April 6, 2023. The event focuses on how proteomics and AI advancements can enhance drug discovery. Patrick Schneider, President and COO, will join a panel discussion at 10:30 AM ET, while CEO Jeff Hawkins and Dr. Schneider will engage in a fireside chat at 2:30 PM ET. Interested parties can access live and archived webcasts from the Investors section of the Quantum-Si website.

Quantum-Si (Nasdaq: QSI) reported its Q4 and FY 2022 results, highlighting a net loss of $33.1 million for Q4 and $132.4 million for the full year. The company launched its Platinum™ protein sequencing system and started shipments in Q1 2023. It has a projected cash runway extending into 2026, with $351.3 million in cash and equivalents as of year-end 2022. Key partnerships were formed, including collaborations with Aviva Systems Biology and Biovista. R&D expenses increased significantly, totaling $72.1 million for the year, largely due to personnel costs and product development. Adjusted EBITDA was negative $100.6 million for 2022.

Quantum-Si Incorporated (NASDAQ: QSI), known as The Protein Sequencing Company^TM, will participate in the 43rd Annual Cowen Health Care Conference in Boston, MA, from March 6-8, 2023. Management will present on March 7, 2023, at 9:10 AM ET. A live and archived webcast of the presentation will be accessible in the Investors section of the Quantum-Si website.

Quantum-Si focuses on advancing proteomics technology through its innovative semiconductor chip, intended to enhance single-molecule protein sequencing and promote drug discovery and diagnostics.

Quantum-Si Incorporated (QSI), known as The Protein Sequencing Company, will report its financial results for Q4 and full-year 2022 on March 6, 2023, before the market opens. The company will host a conference call at 8:30 AM ET on the same day to discuss these results along with a business update. Quantum-Si focuses on innovative proteomics technology, utilizing a unique semiconductor chip aimed at advancing drug discovery and diagnostics beyond traditional DNA sequencing methods. Further details and a replay of the call will be accessible through the company's website.

Quantum-Si Incorporated (NASDAQ: QSI) has announced the commencement of commercial shipments for its Platinum protein sequencing system. The company formed partnerships with Aviva Systems Biology and Biovista to enhance its protein sequencing research capabilities. Additionally, Quantum-Si reaffirmed its commitment to financial discipline, aiming to extend its cash runway beyond 2024. CEO Jeff Hawkins highlighted the launch as a pivotal transition from technology development to market delivery. The company will present updates at the 41st Annual J.P. Morgan Healthcare Conference on January 12.

Quantum-Si (NASDAQ: QSI) has announced a partnership with Aviva Systems Biology to develop protein enrichment kits aimed at enhancing protein sequencing capabilities. These kits will integrate with existing workflows, allowing researchers to investigate proteoforms through Quantum-Si's Platinum protein sequencing platform. CEO Jeff Hawkins emphasized the importance of protein function in understanding biological processes, while Aviva's President Kevin Harvey highlighted the collaboration's potential to accelerate discoveries in protein research.